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SaudiAbstract Background and objective: On the basis that the inflammatory effects of TNF (tumour
necrosis factor) are predominantly mediated through interaction with the TNF receptor-1
(TNFRSF1A), the current study was designed to establish the prevalence of the mutations,
R92Q and P46L TNFRSF1A polymorphisms both in the general healthy Saudi population, and
in Saudi patients carrying inflammatory diseases such as atherosclerosis or rheumatoid arthritis.
We felt it important to report the frequency of the mutations, R92Q and P46L TNFRSF1A poly-
morphisms in healthy Saudi individuals, and those with inflammatory conditions, as well as to
describe the pattern of immunological factors in individuals expressing R92Q or P46L TNFRSF1A.
Patients and methods: We collected in PAX gene blood RNA tubes (for RT-PCR and sequencing)
500 blood samples from normal healthy individuals from the West and Center of Saudi Arabia, as
well as 100 from patients with atherosclerosis, and 100 patients diagnosed with rheumatoid arthri-
tis. All were screened for the levels of soluble TNF, C-reactive protein (CRP), interleukin6 (IL-6)
and sTNFR1. In addition, they were screened for R92Q and P46L TNFRSF1A by RT-PCR. More-
over, phenotype and expression of peripheral blood mononuclear cells (PBMCs) was performed by
flow cytometry (FACS). Results: Across 500 normal individuals, 8 (1.6%) expressed both R92Q and
P46L mutations. By contrast, of the 100 patients in our study with atherosclerosis, 34% expressed
both the R92Q and P46L mutations, whilst 42% of patients with rheumatoid arthritis expressed
both mutations R92Q and P46L. No significant differences were observed between cell markers
of normal individuals (CD3, 4, 8, 16, 56, 19, 25, ICAM-1, VLA-4 & L-selectin) and patients with
atherosclerosis. There were significantly high values of cell markers in patients with rheumatoid
arthritis compared with normal individuals both in terms of percentage and absolute counts
(p< 0.05). Soluble IL-6 and sTNFR1 showed significant decreases in atherosclerosis and rheuma-
toid arthritis when compared with controls (p< 0.05). In addition, CRP and sTNF showed signif-
icant increases in the atherosclerosis and rheumatoid arthritis groups when compared to controls
(p< 0.05). Conclusion: Our findings reasonably anticipate the presence of TRAPS disease (low pen-
768 F.Q. Alenzietrance mutations) amongst the Saudi population although further studies are needed to confirm
these results.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
On the basis that the inflammatory effects of TNF (tumour
necrosis factor) are predominantly mediated through interac-
tion with the TNF receptor-1 (TNFRSF1A) (Paleolog et al.,
1994), the current study was designed to establish the preva-
lence of the mutations, R92Q and P46L TNFRSF1A polymor-
phisms both in the general healthy Saudi population, and in
Saudi patients carrying inflammatory diseases such as
atherosclerosis or rheumatoid arthritis.
The relationship between TNFRSF1A and a variety of dis-
eases is interesting and incompletely understood. For example,
mutations in the ecto-domain of TNFRSF1A cause an autoso-
mal dominant auto-inflammatory condition called TNF recep-
tor associated periodic syndrome (TRAPS; MIM 142680)
(McDermott et al., 1999), and which is typified by periodic
fevers and a variety of tissue manifestations including abdom-
inal pains, myalgia and erythematous skin rashes. Up to 15%
of patients can get the life-threatening complication of amyloi-
dosis. There are more than 50 variants of TNFRSF1A associ-
ated with TRAPS most of which are high penetrance
mutations only seen in TRAPS patients and never in the gen-
eral population. There are, however, two TNFRSF1A variants
that do occur (rarely and asymptomatically) in the general
population, although they were initially identified in TRAPS
patients. As such, they represent low penetrance allelic poly-
morphisms. These polymorphic forms have the substitutions
R92Q (glutamine replacing arginine at position 92) and P46L
(leucine replacing proline at position 46). It is known that
the R92Q and P46L forms of TNFRSF1A have an occurrence
of approximately 1–2% (Aksentijevich et al., 2001; Ravet
et al., 2006), although the P46L variant has been identified in
almost 10% in a sub-Saharan population (Tchernitchko
et al., 2005), and in almost 3% of Arabs living in North Africa
(Dode et al., 2002).
Clinically, TRAPS associated with the high penetrance
TNFRSF1A mutations represent more serious challenges to
treat than in patients where TRAPS is associated with R92Q
and P46L TNFRSF1A (Ravet et al., 2006). Also, the R92Q
TNFRSF1A polymorphism appears to be both a susceptibility
factor, and a disease-modifying factor, which impacts more
common, inflammatory diseases. For example, it has been
demonstrated that R92Q allele occurs in approximately 5%
of patients with rheumatoid arthritis (Aksentijevich et al.,
2001), and as many as 4% of patients with atherosclerosis
(Poirier et al., 2004). The R92Q TNFRSF1A polymorphism
has been linked to extra-cranial deep vein thrombosis in
patients with Behcet’s disease (Amoura et al., 2005), and also
to manifestation of amyloidosis in juvenile idiopathic arthritis
(Aganna et al., 2004).
Mechanistically, immunohistochemistry has shown that
inflammatory tissue changes in TRAPS patient studies relate
to an involvement of monocytes and macrophages in the
inflammatory process. This was further supported by theobservation that the myalgia suffered by individuals with
TRAPS is due to a monocytic fasciitis and not myositis.
We therefore felt it important to report the frequency of
the mutations, R92Q and P46L TNFRSF1A polymorphisms
in healthy Saudi individuals, and those with inflammatory
conditions, as well as to describe the pattern of immunolog-
ical factors in individuals expressing R92Q or P46L
TNFRSF1A.
2. Patients and methods
We collected in PAX gene blood RNA tubes (for RT-PCR and
sequencing) 500 blood samples from normal healthy individu-
als from the West and Center of Saudi Arabia, as well as 100
from patients with atherosclerosis, and 100 patients diagnosed
with rheumatoid arthritis.
The 100 Saudi patients diagnosed with rheumatoid arthritis
were unrelated to each other. There were 28 males and 72
females; their age range was between 20 and 71 years. The
100 Saudi patients with atherosclerosis were also unrelated
to each other, and comprised of 34 males and 66 females; their
age range was between 26 and 65 years. The control group
consisted of 500 unrelated, healthy blood donors, and com-
prised of 300 males and 200 females; their age range was
between 25 and 65 years. Patients with other inflammatory/
autoimmune diseases were not included in the study. Ethical
approval for this study was obtained from research and ethics
committee of PSMMC. Informed written consent was
obtained from each subject before their recruitment onto this
study.
Blood was collected in plain tubes for ELISA to detect
soluble-TNFR1, IL-6, TNF and CRP. Three 3ml of blood
was collected in tubes containing EDTA as anticoagulant for
performing different CD analyses.2.1. Measurement of soluble TNF-R1, CRP and cytokines (IL-6
and TNF)
This was achieved with a BioSource ELISA kit (BioSource
Europe S.A). Samples of serum were diluted 1/100 in diluent.
Then, 50 ll (of each standard, control and samples) were
added to coated wells and incubated at room temperature with
shaking, and then washed. Next, 200 ll of anti s-TNF-R1,
TNF, IL-6 or CRP conjugate solution were added to all wells
and the plate was incubated at room temperature on a hori-
zontal shaker set at 7000 rpm. Following this, the plate was
washed three times by aspirate and 400 ll of wash buffer
was added to each well. Finally, 50 ll of chromogenic solution
was added to all wells after which plates was incubated at
room temperature in the dark for 30 min, after which 200 ll
of stop solution was added to each well. Plates were read by
an ELISA machine (Molecular Device, UK) and observing
the absorbance of the plate at 450 nm within 30 min.
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PAX gene Blood RNA kits were used for purification of total
RNA from 2.5 ml whole blood collected in a PAX gene Blood
RNA Tube (BRT) for RT-PCR.
2.3. Procedure for isolation of mRNA from the samples to study
the mutations in sTNF receptor 1
The BRT was centrifuged to pellet nucleic acids which were
then washed and resuspended. Pellets were incubated in opti-
mized buffers together with proteinase K (PK) to allow protein
digestion. An additional centrifugation through the PAX gene
shedder spin column (PSC) was carried out to homogenize the
cell lysate and to remove residual cell debris. The supernatant
of the flow-through fraction was transferred to a fresh micro-
centrifuge tube and ethanol was added to adjust binding con-
ditions. The lysate was applied to a PAX gene RNA spin
column (PRC) and, during a brief centrifugation, RNA was
selectively bound to the PAX gene silica-gel membrane whilst
contaminants passed through. Remaining contaminants were
removed in several efficient wash steps. Between the first and
the second wash steps, the membrane was treated with DNase
I (RNFD) to remove any trace amount of bound DNA. After
the washes, RNA was eluted in buffer and heat-denatured.
2.4. One step RT-PCR (QIAGEN)
This amplifies the DNA, which was formed from mRNA by
reverse transcriptase. Two primers were designed for each
mutation using oligonucleotide primer pair’s specific for exons
3–4 of TNFRSF1A. Specifically because the aim was to focus
on two mutations, R92Q and P46L, two primer pairs were
designed to detect the R92Q in exon 4, whilst 3 primer pairs
were designed to detect the P46L in exon 3 (Table 1). Two
PCR runs were carried out for each sample (template).
One microlitre of enzyme mix (reverse transcriptase and
Taq DNA polymerase), 1 ll of buffer, 1 ll of dNTP mix and
1 ll of samples (mRNA template from PAX gene tube) were
added into 46 ll of RNase free water. This mix was added
together in one microfuge tube (master mix). 50 ll from master
mix of each sample were added to the PCR tube. The samples
were transferred to PCR machine (Techne, UK) that had been
preheated to 75 C, and run on a PCR reaction programme
(94 C, for 50 s, 50 C for 1 min, 72 C for 1 min)  35, and
72 C for 5 min. One aliquot, used as a negative control, wasTable 1 Sequences of the primers.
Primers Sequence (
TNFRSF1A-R92Q-1-F GCT GCT
TNFRSF1A-R92Q-1-R GGT TTT
TNFRSF1A-R92Q-2-F GAT GAC
TNFRSF1A-R92Q-2-R CCA TGC
TNFRSF1A-P46L-1-F CTT GTG
TNFRSF1A-P46L-1-R CTT TCG
TNFRSF1A-P46L-2-F GGG CTC
TNFRSF1A-P46L-2-R CTG ACT
TNFRSF1A-P46L-3-F TGT GTT
TNFRSF1A-P46L-3-R CCT GTGleft with no template. Five microlitres of PCR products were
used for loading and gel electrophoresis.
2.5. Gel electrophoresis and transillumination
Gel electrophoresis was performed to confirm the appearance
of the bands of the PCR products at 50 base pair (bp) length
after the PCR reaction. Five microlitres of PCR product were
added to 2 ll of loading buffer (0.25% bromophenol blue,
0.25% xylene cyanol FF, 15% Ficol in water). The agarose
gel was prepared (2% agarose in TBE buffer with ethidium
bromide 0.2 ll/ml). The TBE buffer was prepared (90 mM
Tris, 90 mM borate and 2 mM EDTA pH 8.3) and the gel
was placed in the gel electrophoresis tank, immersed with
TBE buffer, and then loaded with the samples. The loaded
gel was run at 80V for 45 min. The loaded gel was observed
under UV-trans-illumination and photographed.
2.6. Sequencing – pre-sequencing enzyme treatment
In order to prepare the samples for the sequencing reaction,
0.5 ll of ExonucleaseI (10 U/ll) and 1 ll of SAP (shrimp alka-
line phosphatase) (1 U/ll) were added to 5 ll of the PCR prod-
uct. This mix was run on the enzyme treatment programme
(37 C for 15 min, 80 C for 15 min) in a Techne PCR
machine.
2.7. Sequencing reaction
One microlitre of enzyme treated PCR product was added to
4 ll of Big Dye terminator, 0.5 ll of primer and 5 ll of sterile
de-ionized water. This mix was run on a sequencing reaction
programme (96 C for 30 s, 50 C for 15 s, 60 C for
4 min)  25, and then 28 C for 1 min.
2.8. Pre-sequencing cleaning
Ten microlitres of sequencing reaction product were purified
by adding 124 ll of sequence cleaning mixture (ethanol:wa-
ter:3 M sodium acetate pH 4.6–5.2 in a dilution 25:5:1). The
samples were centrifuged at 4 C and 20,000g for 15 min.
The supernatant was removed and the pellet cleaned by
300 ll of 70% ethanol. The samples were centrifuged. The
supernatant was removed and the pellet cleaned by ethanol
and re-centrifuged. The supernatant was removed and the
samples dried for the sequencing cycle. The cleaned samplesin the 50 to 30 direction)
CCA AAT GCC GAA AG
CAC TCC AAT AAT GCC G
ATC CAC CAG AAG CGC ATG G
GCT TCT GGT GGA TGT CAT C
TTC TCA CCC GCA G
GCA TTT GGA GCA GC
CTT CCT TGT GTT CT
CTC CTG CCT GTG C
CTC ACC CGC AGC CTA AC
CAC ACT CAC CCT TTC
770 F.Q. Alenziwere processed through the sequencing cycle by mixing them
with POP7 polymer (ABI) and injecting them into sequencer
machine (Applied Biosystem ABI, with 4 channels).
2.9. Flow cytometry analysis
Using a BD FACS Calibur by a direct immunofluorescence
technique, flow cytometry analysis was used to assess the fol-
lowing cell surface markers; CD3, CD4, CD8, CD25 (Reg
T), CD56 (NK), CD69 (gamma/delta T), CD14, CD16,
CD19, ICAM-1, VLA-4, and L-selectin. Analyses were per-
formed for all samples. This analysis was conducted on whole
blood, and the lysis of erythrocytes was achieved using FACS
lysing solution (10) (BD catalogue No. 356457). The values
were expressed as percentage and their absolute counts were
calculated. All CDs were run along with negative isotypic con-
trols (IgG1/IgG2).
2.10. Statistical analysis
Statistical analysis was carried out using SPSS version 16.
Quantitative data were described in the form of mean ± SD,
median and range. Comparisons between groups were per-
formed using an independent t test, the Mann–Whitney U test
was used for data that were not normally distributed. A
p> 0.05 was considered not to be statistically significant
whilst a p< 0.05 was considered significant. A statistical anal-
ysis of the sequencer and flow cytometry machines were carried
out by their own software.
3. Results
3.1. RT-PCR
In normal individuals, 8 of 500 samples (1.6%) expressed both
R92Q and P46L mutations. In contrast, of the 100 patients
with atherosclerosis, 34% expressed both the R92Q and
P46L mutations. In addition, 42% of the 100 patients with
rheumatoid arthritis expressed both mutations (Fig. 1).Figure 1 RT-PCR of samples of normal individuals and of patients
blank).
Table 2 Laboratory parameters in different groups studied.
Marker Control group median (range) Rheuma
IL-6 pg/ml 5 (0.5–16.6) 34.2 (3.5
sTNFR1 ng/ml 0.4 (0.8–1.9) 0.1 (0–0.
CRP mg/dl 2 (1–4) 11.1 (2–3
sTNF pg/ml 3.2 (0–7.3) 10 (6–453.2. Levels of IL-6, sTNFR1, TNF and CRP in different groups
studied
A significant increase in IL-6 was noted in the group of
patients with rheumatoid arthritis when compared to the con-
trols p< 0.001. Conversely, IL-6 in patients with atherosclero-
sis showed no significant difference. STNFR1 showed
significant decreases in both atherosclerosis and rheumatoid
arthritis groups when compared to controls (p< 0.05). CRP
showed significant increases in both RA & AS groups when
compared to the control group (p< 0.05). sTNF showed
highly significant increases in both atherosclerosis and
rheumatoid arthritis groups when compared to controls
(p< 0.001). IL-6 and sTNFR1 in both atherosclerosis and
rheumatoid arthritis groups had mutations and showed signif-
icant decreases when compared to controls (p< 0.05). 3/8 of
those with mutations showed low values of sTNFRSF1A.
The CRP and TNF in both atherosclerosis and rheumatoid
arthritis groups showed significant increases when compared
to controls (p< 0.05). Also, 2 healthy individuals with muta-
tions showed high values of CRP (data not shown).
3.3. Cell surface marker analysis by flow cytometry
We found significantly higher levels of cell markers in patients
with rheumatoid arthritis compared with normal individuals
both in terms of percentage and absolute values (p< 0.05)
(Table 2) (Fig. 2). However, no significant differences between
cell markers of normal individuals and patients with
atherosclerosis were noted (Table 3).
4. Discussion
The two TNFRSF1A variants, R92Q and P46L, were initially
identified in TRAPS patients. These are variants which occur
only in a small percentage of the general population, and
who have no symptoms of TRAPS, and can thus be regarded
as low penetrance allelic polymorphisms. In the current study,
we found that 8 out of 500 normal individuals (1.6%)with atherosclerosis and with rheumatoid arthritis (sample 1 is a
toid arthritis median (range) Atherosclerosis median (range)
–233) p< 0.005 4.5 (0.5–16) p> 0.05
3) p< 0.05 0.1 (0–0.2) p< 0.05
7) p< 0.05 10 (3–35) p< 0.05
) p< 0.001 5 (2–9) p< 0.001
Figure 2 Probability data of cell markers in normal individuals and patients with atherosclerosis and rheumatoid arthritis who express
mutations in TNFR1 (R92Q and P46L).
Table 3 Descriptive data of cell markers in normal individ-
uals and patients (atherosclerosis and rheumatoid arthritis)
who were positive to mutations (R92Q and P46L).
Cell markers
(% and
absolute)
Mean ± SD of
normal
individuals
Mean ± SD
of AS
Mean ± SD
of RA
CD3% 73.6 ± 11.5 74.5 ± 15.4 90 ± 10**
CD3 abs. 2371.8 ± 768 2330 ± 690 3600 ± 846**
CD4% 31.5 ± 10 31 ± 13 62 ± 18**
CD4 abs. 998 ± 402 1010 ± 554 2080 ± 654**
CD8% 28.6 ± 10.4 28.5 ± 9.8 55 ± 15.5**
CD8 abs. 909 ± 412 930 ± 510 1725 ± 496**
CD4/8 Ratio 1.7 ± 0.5 1 ± 0.4 2.5 ± 0.9**
CD16% 18.9 ± 7.9 17 ± 7.1 46 ± 13.3**
CD16 abs. 609.8 ± 326 520.6 ± 243 1200 ± 467**
CD69% 16.5 ± 7.5 15 ± 6.8 36 ± 12.3**
CD69 abs. 541.0 ± 292 455 ± 280 1320 ± 410**
CD25% 79.1 ± 13.4 75.3 ± 12.2 99 ± 1**
CD25 abs 2582 ± 880 2875 ± 790 3488 ± 1119**
CD56% 20.6 ± 10.3 23.1 ± 11.1 38.2 ± 14.4**
CD56 abs 743 ± 310 718 ± 348 1149 ± 401**
CD14% 11.3 ± 4.3 13.3 ± 5.1 16.5 ± 5.2**
CD14 abs 414.6 ± 215 312.6 ± 186 690 ± 254**
CD19% 18.6 ± 8 22.1 ± 7.8 31.2 ± 11.6**
CD19 abs 655.3 ± 302 601 ± 280 987 ± 298**
ICAM-1% 63.4 ± 9.6 62.3 ± 8.8 88.9 ± 10.1**
ICAM-1 abs 1987 ± 434 2258 ± 486 2687 ± 523**
VLA-4% 9.1 ± 2.2 7.9 ± 1.8 18.2 ± 3.9**
VLA-4 abs 313 ± 41 352 ± 48 475 ± 62**
L-selectin% 28 ± 6.7 27 ± 6.8 33 ± 7.9
**
L-selectin abs 1267 ± 261 1251 ± 281 1612 ± 301
**
** p< 0.05.
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amongst patients 34% of patients with atherosclerosis and
42% of patients with rheumatoid arthritis expressed both these
mutations. These findings lead us to conclude that the presence
of TRAPS disease is likely to exist amongst the Saudi
population.
In this study, TNFRSF1A was significantly decreased in
patients with atherosclerosis and rheumatoid arthritis who
had mutations (as compared to healthy individuals). In addi-
tion, 3/8 of normal individuals with mutations showed low val-
ues of sTNFRSF1A. It has been suggested that low levels of
sTNFRSF1A may be the result of defective cleavage of the
mutant receptor from the surface of activated cells
(McDermott et al., 1999; Galon et al., 2000). Accordingly, it
was suggested that the abnormally low levels of sTNFRSF1A
circulating in patients with TRAPS may be insufficient to neu-
tralize circulating TNF effectively, and which may therefore
result in an exaggerated inflammatory response when the
blood level of TNF becomes elevated.
When stimulated with TNF, cells from TRAPS patients
actually tend to produce less IL-6 than those of normal indi-
viduals, a finding consistent with our own observations
because the patients with mutations (atherosclerosis and
rheumatoid arthritis) in our study showed significant decreases
of IL-6 when compared to the control group (Aganna et al.,
2003). However, Nowlan et al. (2006), reported IL-6 and IL-
8 levels to be significantly elevated in C33Y TRAPS patients
and more elevated in patients with rheumatoid arthritis. Signif-
icantly high levels of CRP have been found in patients with
mutations who have atherosclerosis and rheumatoid arthritis,
as well as in 2 healthy individuals with mutations. These find-
ings are in line with previous work which reported that plasma
laboratory findings in TRAPS were associated with typical
inflammatory episodes (Aganna et al., 2003).
We found no significant difference between cell markers of
normal individuals and patients with atherosclerosis (Table 2)
(Fig. 2). In contrast, we noted significantly high values of cellmarkers in patients with rheumatoid arthritis compared to
normal individuals, and we found that these data correlated
with the presence of acute or chronic inflammation in patients
772 F.Q. Alenziwith rheumatoid arthritis, where elevated migration of inflam-
matory cells would be expected.
Our results, especially when taken together with other
research that has supported the association between TNF
polymorphism and rheumatoid arthritis (Al-Mohaya et al.,
2015; AlOkaily et al., 2015; Nasr et al., 2014; Alkhuriji et al.,
2013; Al-Harthi et al., 2013 Jul 8; Al-Rayes et al., 2011), sup-
port the notion that proinflammatory cytokines and markers
are potent inducers of inflammation, and further, that elevated
levels of these cytokines, being frequently associated with the
activation of macrophages, thereby influence the severity of
inflammatory responses. We suggest that these results might
well have prognostic utility for future clinical studies, and that
TNFR polymorphism may serve as a guideline in determining
the clinical response to anti-TNF-a therapy.
In conclusion, these data may reasonably anticipate the
presence of TRAPS disease (low penetrance mutations)
amongst the Saudi population although further studies are
needed to confirm these results.
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